Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 36INDUSTRY 21NETWORK 15NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Sarcoma 2Wilms Tumor 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Neuroblastoma 1Neoplasms 1Carcinoma, Hepatocellular 1Brain Neoplasms 1

Interventions

Cyclophosphamide 385Specimen Handling 370Magnetic Resonance Spectroscopy 325Radiotherapy 306Biopsy 269Cisplatin 257Carboplatin 253Paclitaxel 235Doxorubicin 226Fluorouracil 200Etoposide 197Vincristine 182Bevacizumab 180Filgrastim 170Gemcitabine 163Leucovorin 149Cytarabine 144aldesleukin 140Taxes 127Docetaxel 122Oxaliplatin 113Chemotherapy, Adjuvant 113fludarabine phosphate 111Rituximab 107Methotrexate 107Radiation 106Bortezomib 105Prednisone 102Irinotecan 100Dexamethasone 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Interventional × Trabectedin × Clear all
NCT01453283 2017-07-02

Tabectedin to Treat Children and Adolescents With Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
12 enrolled
CNSGastrointestinalGenitourinarySarcoma

Brain Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing

NCT00017030 2013-06-26

Ecteinascidin 743 in Treating Patients With Unresectable Advanced or Metastatic Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 2 Completed
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡